148 related articles for article (PubMed ID: 26234767)
1. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
[TBL] [Abstract][Full Text] [Related]
2. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
Fujiki H; Sueoka E; Watanabe T; Suganuma M
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
[TBL] [Abstract][Full Text] [Related]
3. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
[TBL] [Abstract][Full Text] [Related]
4. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; Saramäki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
5. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
[TBL] [Abstract][Full Text] [Related]
7. Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
Routila J; Mäkelä JA; Luukkaa H; Leivo I; Irjala H; Westermarck J; Mäkitie A; Ventelä S
Genes Chromosomes Cancer; 2016 Jan; 55(1):69-81. PubMed ID: 26395031
[TBL] [Abstract][Full Text] [Related]
8. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
10. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells.
Pallai R; Bhaskar A; Barnett-Bernodat N; Gallo-Ebert C; Pusey M; Nickels JT; Rice LM
Tumour Biol; 2015 Aug; 36(8):6383-90. PubMed ID: 25833693
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Huang J; Jia J; Tong Q; Liu J; Qiu J; Sun R; Yao L; Yang C
Tumour Biol; 2015 Mar; 36(3):1589-94. PubMed ID: 25377160
[TBL] [Abstract][Full Text] [Related]
14. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
16. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
17. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
[TBL] [Abstract][Full Text] [Related]
19. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
20. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
